According to FutureWise analysis the market for non-hodgkin lymphoma treatment is expected to reach US$ 18.91 billion by 2031 at a CAGR of 8.70%.
Non-Hodgkin lymphoma is a cancer that affects the white blood cells. This reduces the immunity of the patient. This type of cancer is severe which has encouraged an extensive research for developing treatment method that are effective and efficient. This has increased the number of investments made for its research, thereby propelling the non-hodgkin lymphoma treatment market growth. Additionally, the rising awareness regarding the disease, bolstered drug pipeline for the disease treatment and improvements in the diagnostic methodologies for detecting lymphoma and the rising occurrence of NHL, thereby propelling the market growth.
As per the American Cancer Society, NHL is prevalent in the United States that covers over 5% of all the cancers. Radiation therapy is used for treating NHL in its earlier stages. Radiation therapy, along with chemotherapy, is used for treating advanced lymphomas and in case of a widespread HNL, palliative radiotherapy is primarily preferred. Furthermore, as per the Leukemia and Lymphoma Society, 2019, over 80,000 new lymphoma cases were registered, out of which over 74,000 were NHL cases. Additionally, it is projected that over 870,000 people in the United are identified with lymphoma. Moreover, strategic collaborations for cancer therapeutics has bolstered the market growth. For example, Amgen Inc., in 2015, partnered with MerckCo. Inc. to bolster a cancer immunotherapy phase 3 study, investigating Blincyto in combination with Keytruda in people with Diffuse Large B-Cell Lymphoma, a more prevalent NHL.